Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Sep 4:4:241.
doi: 10.3389/fonc.2014.00241. eCollection 2014.

Therapeutic advancements in multiple myeloma

Alessandro Gozzetti  1 , Veronica Candi  1 , Giulia Papini  1 , Monica Bocchia  1
Affiliations
Review

Therapeutic advancements in multiple myeloma

Alessandro Gozzetti et al. Front Oncol. .

Abstract

Multiple myeloma survival has significantly improved in the latest years due to a broad spectrum of novel agents available for treatment. The introduction of thalidomide, bortezomib, and lenalidomide together with autologous stem-cell transplantation has considerably increased complete remission rate and progression-free survival resulting ultimately in prolonged survival in myeloma patients. Moreover, novel strategies of treatment such as consolidation and maintenance are being used to further implement responses. Finally, a number of new drugs such as carfilzomib and pomalidomide are already in clinical practice, making the future of myeloma patients brighter.

Keywords: IMID’s; bortezomib; elderly; multiple myeloma; new therapies; young.

PubMed Disclaimer

References

    1. Kyle RA, Rajkumar SV. Multiple myeloma. Blood (2008) 11:2962–7210.1182/blood-2007-10-078022 - DOI - PMC - PubMed
    1. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood (2008) 111:2521–610.1182/blood-2007-08-104984 - DOI - PubMed
    1. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood (2008) 111:2516–2010.1182/blood-2007-10-116129 - DOI - PMC - PubMed
    1. Gozzetti A, Cerase A, Lotti F, Rossi D, Palumbo A, Petrucci MT, et al. GIMEMA (Gruppo Italiano Malattie Ematologiche dell’Adulto) myeloma working party extramedullary intracranial localizations of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients. Cancer (2012) 118:1574–8410.1002/cncr.26447 - DOI - PubMed
    1. Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R, et al. New drugs and novel mechanisms of action in multiple myeloma 2013: a report from the International Myeloma Working group (IMWG). Leukemia (2014) 28:525–4210.1038/leu.2013.350 - DOI - PMC - PubMed

LinkOut - more resources